TY - JOUR
T1 - Evaluation of isradipine (PN 200-110) in mild to moderate hypertension
AU - Winer, Nathaniel
AU - Thys-Jacobs, Susan
AU - Kumar, Raminder
AU - Davidson, Warren D.
AU - Grayson, Martha
AU - Harris, Calvin
AU - Walker, Deborah
AU - Itskovitz, Harold
AU - Gonasun, Leonard
PY - 1987/10
Y1 - 1987/10
N2 - The efficacy and safety of isradipine (PN 200-110), a new dihydropyridine calcium antagonist, was evaluated in 87 hypertensive patients in a placebo-controlled, double-blind, randomized multicenter trial. After a 3-week single-blind washout phase, isradipine (or matching placebo) was administered for 4 weeks, beginning at 2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals if supine diastolic blood pressure remained ≥90 mm Hg. At the end of 1 week average supine blood pressure in the isradipine group (n = 45) fell from a baseline of 156 ± 13 104 ± 4 mm Hg to 146 ± 14 97 ± 7 mm Hg. By week 4 blood pressure was reduced by 19 14mm Hg compared with 4 5mm Hg in the placebo group (P < 0.001 between groups). Supine and standing pulse rates were slightly increased initially with isradipine therapy but returned to baseline with increasing isradipine doses. Blood pressure responses at week 4 were good or excellent (supine diastolic ≤90 mm Hg or ≥10 mm Hg decrease from baseline) in 87% of isradipine-treated patients and in 26% of placebo-treated patients. Headache, edema, abdominal discomfort, and constipation occurred slightly more frequently in isradipine-treated patients than in placebo-treated control subjects. The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension.
AB - The efficacy and safety of isradipine (PN 200-110), a new dihydropyridine calcium antagonist, was evaluated in 87 hypertensive patients in a placebo-controlled, double-blind, randomized multicenter trial. After a 3-week single-blind washout phase, isradipine (or matching placebo) was administered for 4 weeks, beginning at 2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals if supine diastolic blood pressure remained ≥90 mm Hg. At the end of 1 week average supine blood pressure in the isradipine group (n = 45) fell from a baseline of 156 ± 13 104 ± 4 mm Hg to 146 ± 14 97 ± 7 mm Hg. By week 4 blood pressure was reduced by 19 14mm Hg compared with 4 5mm Hg in the placebo group (P < 0.001 between groups). Supine and standing pulse rates were slightly increased initially with isradipine therapy but returned to baseline with increasing isradipine doses. Blood pressure responses at week 4 were good or excellent (supine diastolic ≤90 mm Hg or ≥10 mm Hg decrease from baseline) in 87% of isradipine-treated patients and in 26% of placebo-treated patients. Headache, edema, abdominal discomfort, and constipation occurred slightly more frequently in isradipine-treated patients than in placebo-treated control subjects. The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension.
UR - http://www.scopus.com/inward/record.url?scp=0023633115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023633115&partnerID=8YFLogxK
U2 - 10.1038/clpt.1987.175
DO - 10.1038/clpt.1987.175
M3 - Article
C2 - 2959426
AN - SCOPUS:0023633115
SN - 0009-9236
VL - 42
SP - 442
EP - 448
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -